Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAMINA-001: ATG-037 +/- Pembrolizumab in Solid Tumors
NCT05205109Phase 1Recruiting
- Sponsor
- Antengene
- Start
- Jun 2022
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of ATG-037 in solid tumor, melanoma and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Antengene. Primary endpoints: Incidence of adverse events and serious adverse events at 1 year, Dose Limiting Toxicity at 21 days and 2 more. Started Jun 2022; status: recruiting.
02
Drugs
ATG-037
03
Conditions
solid tumormelanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05205109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05205109.